Credit Analysis: Rowan International Limited

1. Credit Opinion: CONDITIONAL

Rowan International Limited presents a mixed credit profile. While the business demonstrates strong turnover growth (£57.5m, +8.8% YoY), operates in a resilient counter-cyclical sector (discount FMCG distribution), and has shown meaningful balance sheet rehabilitation from negative equity positions, the company carries material credit concerns. Net assets of £330k on £57.5m turnover represent an exceptionally thin equity cushion (0.6% net asset ratio). Cash has deteriorated sharply from £1.1m (2024) to £195k (2025), and total liabilities nearly equal total assets, indicating extreme leverage. The recent change of ownership to Transmed Holding Limited and associated refinancing introduces both opportunity (parent company support) and uncertainty (new debt structure).

Recommendation: Credit facilities may be extended but should include financial covenants, parent company guarantees where possible, and enhanced monitoring. Unsecured exposure should be limited. The conditional approval reflects the turnaround progress but acknowledges the fragile balance sheet position relative to the business's scale.

2. Financial Strength

Balance Sheet Analysis

Key Concerns:

• Extreme Leverage: The debt-to-equity ratio is approximately 39:1 (total liabilities of £13m against equity of £330k). This is well beyond acceptable parameters for most commercial lending. The company is essentially trading on creditors and debt facilities.

• Equity Rehabilitation: The progression from (£1.05m) negative shareholders' funds in 2021 to £520k positive in 2025 is encouraging and suggests accumulated profits have been retained to rebuild the balance sheet. However, the equity base remains dangerously thin for a business of this scale.

• Asset Quality: Total assets have grown from £8m to £13.6m over the period, likely driven by stock and trade debtors. For an FMCG residual stock distributor, the quality and realisability of stock is critical – residual stock by definition may have limited secondary market value.

• Share Capital: Share capital of £520k has been maintained, suggesting the recapitalisation came through retained profits rather than fresh equity injection, which is positive for demonstrating earnings quality.

• PSC Structure: Lloyds Investments Group Holdings Limited holds >75% of shares and voting rights, with Rowan International Topco Limited having director appointment rights. This corporate ownership structure following the Transmed acquisition means recourse to individual shareholders is limited – any guarantees would need to come from the parent entity.

3. Cash Flow Assessment

Liquidity Position

Critical Observations:

• Cash Deterioration: The 82% decline in cash from £1.1m to £195k year-on-year is a significant red flag. While this may reflect working capital investment to support sales growth, the absolute cash position is perilously low for a £57.5m turnover business. This provides virtually no liquidity buffer.

• Working Capital Dynamics: The strategic report indicates stock days increased from 47 to 53 days, suggesting either deliberate stock building or slower stock turnover. For a residual stock business, extended stock holding increases risk of write-downs.

• Profit Conversion: Profit after tax of £0.3m (2025) against cash decline of £0.9m suggests poor profit-to-cash conversion. This requires investigation – the cash may have been absorbed by working capital expansion, capital expenditure, or debt servicing following the refinancing.

• Refinancing Impact: The October 2024 transfer to Transmed and subsequent refinancing of inter-company loans to third-party bank debt will have altered the cash flow dynamics. The terms of this new debt facility are not disclosed but are material to creditworthiness.

• Trade Creditor Reliance: With liabilities of £13m against cash of £195k, the business is heavily dependent on trade creditors and/or revolving credit facilities to fund operations. Any withdrawal of supplier credit terms could create an immediate liquidity crisis.

Working Capital Assessment

The business model is inherently working capital intensive – purchasing residual stock upfront and selling into discount channels. The 53 stock days, while not excessive, represents a meaningful cash drag. Combined with debtor days (not disclosed but likely significant given the B2B wholesale model), the working capital funding requirement is substantial relative to the equity base.

4. Monitoring Points

Critical Metrics to Watch:

1. Cash Position: Monthly monitoring essential. Any further deterioration below £100k would represent a material credit concern. Request regular management accounts showing cash flow projections.

2. Net Current Assets: The balance sheet does not clearly separate current and non-current items in the summary data. Request detailed current asset and current liability breakdowns to assess working capital adequacy and current ratio.

3. Debt Facility Terms: Following the Transmed refinancing, obtain details of the third-party bank loan including covenants, maturity, and security. This will be the primary determinant of ongoing solvency.

4. Stock Provisioning: Given the business model (residual FMCG stock), monitor stock write-downs and provisioning closely. Residual stock inherently carries obsolescence risk.

5. Trade Creditor Days: Monitor for any extension of payment terms to suppliers, which could indicate cash flow pressure. Conversely, any reduction in creditor days could signal suppliers tightening terms.

6. Parent Company Support: Clarify the nature and extent of any parent company undertaking or guarantee from Transmed Holding Limited. This is critical for assessing fallback position.

7. Profit-to-Cash Conversion: Track the relationship between reported profits and operating cash flow. The 2025 divergence (profit up, cash down) requires explanation and ongoing monitoring.

8. Customer Concentration: The strategic report references growth in both supplier and customer bases, but no concentration data is provided. Obtain customer and supplier dependency analysis.

9. Gross Margin Stability: Current margins of 17.7% are adequate for the sector but leave limited room for compression. Any margin erosion would disproportionately impact the thin bottom line.

10. Filing Compliance: Accounts are current and not overdue. Monitor for any delays in future filings, which could signal governance concerns.